Spinal bone metastases in colorectal cancer: a retrospective analysis of stability, prognostic factors and survival after palliative radiotherapy by Bostel, Tilman et al.
RESEARCH Open Access
Spinal bone metastases in colorectal
cancer: a retrospective analysis of stability,
prognostic factors and survival after
palliative radiotherapy
Tilman Bostel1,3, Robert Förster1,3, Ingmar Schlampp1,3, Tania Sprave1,3, Thomas Bruckner2, Nils Henrik Nicolay1,3,
Stefan Ezechiel Welte1, Jürgen Debus1,3 and Harald Rief1,3*
Abstract
Background: This retrospective analysis aimed to analyse the stability of spinal bone metastases in colorectal
cancer (CRC) patients following radiotherapy (RT) by use of a validated score and to assess prognostic factors for
stability and survival.
Methods: Ninety-four patients with osteolytic spinal bone metastases from CRC were treated at the
Department of Radiation Oncology at the University Hospital Heidelberg between 2000 and 2014. The
stability of each affected vertebral body was assessed according to the validated Taneichi bone stability
score on the basis of the treatment planning CT scan prior to RT and also based on the follow-up CT
examinations at 3 and 6 months after RT. Additionally, bone survival rates (time between first day of RT
and death from any cause) as well as prognostic factors for bone survival were evaluated for all study
patients.
Results: Before RT, 59 patients (63%) were rated unstable according to the Taneichi score. Pathological
fractures within the irradiated region were diagnosed in 43 patients (46%) prior to RT. New fractures or
progression of previously collapsed vertebrae were diagnosed in 4 patients (4%) after irradiation. Significant
re-calcification and stabilization of former unstable bone metastases was only observed in 3/59 patients
(3%) and 5/59 patients (9%). The median bone survival was 4.2 months (range 0.5–67.3 months) and
6 months after RT 61% of the patients were dead. Karnofsky performance score (KPS) (< 70% vs. ≥ 70%),
chemotherapy and bisphosphonate therapy were predictive prognostic factors for bone survival.
Conclusions: Our study population is characterized by poor bone survival and low re-calcification rates of
unstable spinal bone lesions 3 and 6 months after RT. To avoid unnecessary hospitalisation and improve
remaining QoL, short fractionated treatment schedules of RT may be prefered in this highly palliative
situation, particularly for patients with a KPS < 70%.
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Background
Colorectal cancer (CRC) is one of the most common
cancers worldwide, with more than 1 million new cases
per year [1]. While the prognosis of CRC has improved
over the last decade with the advent of neoadjuvant
treatment regimes and the introduction of targeted
agents, the metastatic form of CRC remains to have a
poor prognosis with a 5-year survival rate of only 10%
[1]. It is well known that the most common target sites
for metastatic spread are the liver and the lungs [2–4].
Skeletal involvement is also a relative frequent finding in
metastatic CRC, and is mostly associated with distant
metastases in other organs such as liver or lung [5–7].
Up to 5, 5% of all CRC patients have bone metastasis at
the time of initial diagnosis and up to 27% will develop
bone metastasis during the course of their disease [2, 5, 6];
the most common localization of bone metastases is the
vertebral column [8]. Due to novel treatment approaches
for patients with metastatic CRC, the median survival of
affected patients has increased significantly, and as a
consequence, patients have a higher risk not only to
develop bone metastases but also to experience complica-
tions arising from metastatic bone destruction, such as
pain, pathological fractures, spinal cord compression
or hypercalcemia [9–16]. These skeletal-related events
have the potential to severely affect patients’ quality
of life (QoL) [17].
The treatment of bone metastases requires a multidis-
ciplinary approach employing surgery, systemic treat-
ment or radiotherapy [18]. Pain, existing or impending
instability, neurological symptoms due to compression
of the spinal cord, or previous surgical intervention form
the main indications for radiotherapy (RT). RT offers
pain relief in 50–80% of patients [19].
Besides pain, impaired stability of metastatic verte-
bral bodies can result in severe complications and
therefore strongly affect patients’ QoL. Insufficient
stabilization of the metastatic vertebral column may
lead to severe disability from pathologic fractures;
however, commonly prescribed surgical corsets add a
significant immobilization to already existing pain
symptoms. Recently, we reported on patients with
lung cancer, breast cancer and pelvic gynecologic
malignancies in which a significant response towards
RT in terms of stability could be demonstrated [20, 21, 22].
The benefit of RT concerning pain and recalcification
of osteolytic metastases may be increased when the
therapy is combined with concomitant administration
of bisphosphonates [23, 24].
The aim of this retrospective analysis was to sys-
tematically assess the bone lesions resulting from
CRC in terms of stability, fractures before and after
RT, survival, and predictive factors for stability and
survival.
Methods
Ninety-four patients with bone metastases of the thor-
acic and lumbar spine resulting from CRC were treated
at the Department of Radiation Oncology at Heidelberg
University Hospital between February 2000 and July
2014. Patients’ data were taken from the cancer registry
of the National Center for Tumour Diseases (Heidelberg,
Germany). Patients underwent regular follow-up exami-
nations including computed tomography (CT) imaging.
Diagnosis was based on CT, magnetic resonance imaging
(MRI) or bone scintigraphy findings. The evaluated
osteolytic bone metastases had to be located in the
thoracic or lumbar spine.
The stability of each affected vertebral body was
assessed according to the validated Taneichi bone stabil-
ity score on the basis of the treatment planning CT scan
prior to RT and also based on the follow-up CT exami-
nations at 3 and 6 months after RT [25]. This scoring
system constitutes a simple method for classifying osteo-
lytic metastases in vertebral bodies as “stable” or “un-
stable” by definition of risk factors such as tumor size and
the degree of costovertebral joint destruction for the thor-
acic region (Th 1 to 10) and tumor size and the degree of
pedicle destruction for the lumbar region (Th 11 to L5).
Osteolytic metastases were rated on a scale from A to
G, whereby subtypes A to C were defined as stable, and
subtypes D to G as unstable (Fig. 1). In patients with more
than one metastasis per vertebral body, the localization
with the highest Taneichi score was assessed.
Many patients (43%) exhibited more than one affected
vertebral body within the planning target volume (PTV).
Accordingly, 94 patients presenting with a total of 162
bone lesions in the thoracic and lumbar spine were
evaluated. The Karnofsky performance score (KPS) was
used to assess performance status [26]. Many patients
received further treatments such as chemotherapy or
bisphosphonates before, during and after radiotherapy.
The characteristics of all patients included in this study
are summarized in Tables 1 and 2.
RT was planned on the basis of a planning CT
examination and performed over a dorsal photon field
with the energy 6 MV. PTV covered the affected verte-
bral body/bodies as well as the vertebral body immedi-
ately above and below. Median delivered dose was
30 Gy (range 20–40 Gy) in individual treatment
fractions of 3 Gy (2–4 Gy) (Table 2).
Statistical analysis was done using the SAS soft-
ware version 9.3 (SAS Institute, Cary, NC, USA). A
p-value of p < .05 was considered statistically signifi-
cant (Chi square and Log-rank test). Bone survival
was defined as the time between first day of RT for
bone metastases until death from any cause. Survival
was plotted according to the Kaplan-Meier method.
Bowker’s test and kappa statistics were calculated to
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evaluate distribution of the Taneichi score over time.
Univariate logistic regression analysis was performed
to evaluate possible predictors for bone survival.
This analysis was approved by the independent
ethics committee of the Heidelberg University Medical
Faculty (# S-513/2012).
Results
The mean follow-up time was 7.5 months (range 0.5–
67.3 months). Ninety-four patients with a total of 162
bone metastases (range 1–5 metastases/ patient) were
assessed according to the validated Taneichi scoring
system prior to RT and at 3 and 6 months after RT
based on CT imaging. Osseous metastases were located
in the thoracic spine in 60% (n = 56) and in the lumbar
spine in 40% (n = 38) of patients. Pathological fractures
within the irradiated region were diagnosed in 43
patients (46%) prior to RT. New fractures or progression
of previously collapsed vertebrae were diagnosed in 4
patients (4%) after irradiation.
The most frequently observed Taneichi subtype was
D (31%; n = 29) (Fig. 1). None of the initially stable
bone lesions were rated unstable during the course of
follow-up (Table 3).
In contrast, RT could stabilize primary unstable bone
metastases in 5 and 9% of patients after 3 and 6 months
Fig. 1 Taneichi score
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(p = 0.08 and 0.03, McNemar test) (Table 3). In patients
with KPS ≥ 70%, the stabilization rate was higher than in
patients with KPS < 70% after 6 months (16% vs. 0%).
Due to relatively low stabilization rates, the planned
analysis of predictive factors for stabilization was not
possible. Taneichi subtypes improved in 49% (n = 18)
and showed no change in 51% (n = 19) of the patients
who were still alive 6 months after RT. No deterioration
in the scored Taneichi value was observed at the follow-
up examinations compared to the baseline CT scan. The
Bowker test shows the distribution pattern of the sub-
types according to the Taneichi score prior to and 3 and
6 months after RT (Tables 4 and 5). Asymmetry was ap-
parent and correlation was good (weighted kappa = 0.85
and 0.63, Tables 4 and 5).
Thirty-seven patients (39%) were still alive at 6 months
after RT. The median bone survival for the entire patient
cohort was 4.2 months (range 0.5–67.3 months). KPS was
a strong predictive factor for bone survival (p < 0.0001)
(Fig. 2). Median bone survival was 1.7 months (range 0.5–
7.5 months) for patients with a KPS < 70% in contrast to
12.4 months (range 4.3–67.3 months) for patients with a
KPS of ≥70%. The use of bisphosphonates and chemother-
apy were further predictive factors significantly correlated
with bone survival in the univariate analysis (Table 6). The
Table 1 Patients’ characteristics
n %
Age (years)
Median (range) 66 (43–88)
Gender
Female 35 37.2
Male 59 62.8
Karnofsky PS
< 70% 54 57.4
≥ 70% 40 42.6
Number of bone metastases
Mean (range) 1.7 (1–5)
Solitary 54 57.4
Multiple 40 42.6
Spine involvement
Thoracic 56 60
Lumbar 38 40
Primary site
Cecum 4 4.3
Ascending, transverse and descending colon 27 28.7
Sigma 18 19.1
Rectum 45 47.9
Distant extraskeletal metastases
Brain 13 13.8
Lung 61 64.9
Liver 72 76.6
Lymphatic 35 37.2
Others 22 23.4
Abbreviation: Karnofsky PS Karnofsky performance score
Table 2 Treatment
Characteristics n %
RT dose completed (Gy)
Single dose (median, range) 3 (2–4)
Cumulative dose (median, range) 30 (20–40)
Treatment for primary site
Chemotherapy 80 85.1
Targeted therapy 26 27.7
Other treatment for bone metastases
Orthopedic corset 27 28.7
Bisphosphonates 21 22.3
Abbreviations: RT radiotherapy, Gy Gray
Table 3 Results of Taneichi score evaluation
n %
Stability before RT
Unstable 59 63
Stable 35 37
Stability after 3 months
Unstable 27 59
Stable 19 41
Stability after 6 months
Unstable 17 46
Stable 20 54
Abbreviation: RT radiotherapy
Table 4 Test of symmetry for Taneichi score (3 months)
Subtypes 3 months after RT
A B C D E F G Total
Subtypes before RT A 2 0 0 0 0 0 0 2
B 1 6 0 0 0 0 0 7
C 0 3 4 0 0 0 0 7
D 1 0 1 13 0 0 0 15
E 0 0 1 1 7 0 0 9
F 0 0 0 0 0 4 0 4
G 0 0 0 0 0 0 1 1
Total 4 9 6 14 7 4 1 45
This Bowker Test shows the distribution of subtypes of Taneichi-Score before
and 3 months after RT. The evaluation of the distribution of subtypes A to G
shows in some patients minor changes in the direction of improvement over
the course of time. Deterioration occurs in no cases, improvement in 18%
(n = 8). No change is seen in 82% (n = 37) of the patients who were still alive
more than 3 months after RT
Abbreviation: RT radiotherapy
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prevalence of additional visceral metastases, the use of
targeted agents and the number of bone metastases were
not predictive for bone survival (Table 6).
Discussion
The major problems of patients with bone metastasis that
commonly reduce quality of life comprise severe, drug-
resistant pain symptoms, manifest or impending fractures,
tumor-induced hypercalcemia and neurological complica-
tions such as paraplegia.
Therefore, classification of stability of spinal metasta-
ses is a frequent clinical concern. The Taneichi scoring
system is an established tool for the classification of
spinal metastases regarding risk of pathological fracture
or bone instability.
In previous studies, therapeutic effects of palliative RT
on colorectal spinal metastases were only measured in
terms of pain control and improvement of neurological
deficits due to metastatic spinal cord compression [27].
In contrast, there are no existing data concerning the
impact of RT on the stability of spinal metastases due to
colorectal cancer.
Prior to RT, 63% of the patients in this dataset had un-
stable bone metastases of the thoracic or lumbar spine.
After 6 months, palliative RT reached significant re-
ossification and stabilization in only 9% of these bone
lesions.
The reported stabilization rate is relatively poor com-
pared to the stabilization rate of other tumor entities
after palliative RT such as lung or breast cancer and
pelvic gynecological malignancies [19, 22, 23]. In con-
trast, spinal metastases from malignant melanoma and
renal cell carcinoma do not benefit at all from palliative
RT with regard to re-calcification and stabilization of
unstable spinal bone lesions [28, 29].
In our study, the poor stabilization effect of palliative
RT can be explained to a large extent by the limited life
expectancy of the patients. At 6 months after RT, only
39% of patients were still alive. Median survival was
4.2 months after diagnosis of bone metastasis and corre-
sponds well with the results of previously reported pa-
tient cohorts [6, 30, 31]. The very poor bone survival of
CRC patients is explained by the fact that bone metasta-
sis from CRC represents a late event in the evolution of
the disease, with the majority of the patients exhibiting
widely disseminated disease at the time of first diagnosis
of skeletal manifestation [6, 7].
In line with the results of another study [27], we
identified the patients’ performance status as a prog-
nostic factor for predicting bone survival in CRC pa-
tients. A Karnofsky performance status (KPS) < 70%
Table 5 Test of symmetry for Taneichi score (6 months)
Subtypes 6 months after RT
A B C D E F G Total
Subtypes before RT A 2 0 0 0 0 0 0 2
B 5 1 0 0 0 0 0 6
C 3 3 1 0 0 0 0 7
D 1 0 3 9 0 0 0 13
E 1 0 0 1 3 0 0 5
F 0 0 0 0 1 2 0 3
G 0 0 0 0 0 0 1 1
Total 12 4 4 10 4 2 1 37
This Bowker Test shows the distribution of subtypes of Taneichi-Score before
and 6 months after RT. Deterioration of Taneichi-subtypes occurs in no cases,
improvement in 49% (n = 18). No change is seen in 51% (n = 19) of the
patients who were still alive more than 6 months after RT
Abbreviation: RT radiotherapy
Fig. 2 Bone survival depending on the Karnofsky performance score (KPS)
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was significantly associated with an extremely poor bone
survival of less than 2 months. In contrast, patients with a
KPS ≥ 70% had a bone survival of about 12 months. As
recalcification of irradiated osteolytic bone lesions usually
takes up to several months, it is unlikely that patients with
a KPS < 70% will have a benefit in terms of stabilization.
In contrast, patients with a KPS ≥ 70% have a higher
chance for stabilization due to longer life expectancy and
continued mobility-related physical strain to the bones. In
our cohort, 4 out of 25 patients (16%) with initially un-
stable bone lesions and a KPS ≥ 70% were found stabilized
by RT within 6 months.
Additionally, our results showed that patients with
chemotherapy and/or bisphosphonate therapy had an
improved bone survival compared to patients without
these therapies. In 81% of patients, bisphosphonates
were initiated after the end of radiotherapy. In con-
trast, chemotherapy was started prior to RT in 93%
of patients.
In contrast, the absence or presence of visceral metas-
tases, the number of bone metastases and the use of
targeted agents were not statistically significant in the
univariate analysis.
Our study has several limitations, among them the
retrospective character of the dataset. Secondly, due to
the limited number of patients, a statistically sound
multivariate analysis of prognostic factors for bone
survival was not possible. Additionally, the selection
criteria for the application of chemotherapy and
bisphosphonates were retrospectively not available;
therefore, we cannot rule out that the use of both
treatment modalities may be related to a better
performance status rather than being an independent
predictive factor for bone survival. A planned analysis
of prognostic factors for stabilization of initially un-
stable bone metastases was not possible due to the
poor bone survival and low bone recalcification rates
at 3 and 6 months after RT. Due to the limitations of
the Taneichi score, patients with bone metastases from
CRC outside the thoracic and lumbar spine were not
considered.
Summarized, due to the low re-calcification rates
observed in our patient cohort, short course RT appears
preferable for patients with a KPS < 70%, since it pro-
vides similar pain control as protracted schedules. In
contrast, patients with a KPS ≥ 70% may be treated with
more protracted radiation schedules, if the treatment
goal is stabilization, even though the chance for attaining
this objective is relative small compared to other tumor
entities [22, 23].
Conclusion
Patients with bone metastases due to CRC exhibit poor
bone survival and low re-calcification rates of unstable
spinal bone lesions at 3 and 6 months after RT. To avoid
unnecessary hospitalisation and improve QoL, short
fractionated treatment schedules of RT may be prefer-
able in this highly palliative situation, particularly for
patients with a KPS < 70%.
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